{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:06:00Z","timestamp":1790420760699,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj&amp;#x00E4;rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Retention of <jats:sup>18<\/jats:sup>F-Flortaucipir is reportedly increased in the semantic variant of primary progressive aphasia (svPPA), which is dominated by TDP-43 pathology. However, it is unclear if <jats:sup>18<\/jats:sup>F-Flortaucipir is also increased in other TDP-43 diseases, such as bvFTD caused by a <jats:italic>C9orf72<\/jats:italic> gene mutation. We therefore recruited six <jats:italic>C9orf72<\/jats:italic> expansion carriers, six svPPA patients, and 54 healthy controls. All underwent <jats:sup>18<\/jats:sup>F-Flortaucipir PET and MRI scanning. Data from 39 Alzheimer\u2019s Disease patients were used for comparison. PET tracer retention was assessed both at the region-of-interest (ROI) and at the voxel-level. Further, autoradiography using <jats:sup>3<\/jats:sup>H-Flortaucipir was performed. SvPPA patients exhibited higher <jats:sup>18<\/jats:sup>F-Flortaucipir retention in the lateral temporal cortex bilaterally according to ROI- and voxel-based analyses. In <jats:italic>C9orf72<\/jats:italic> patients, <jats:sup>18<\/jats:sup>F-Flortaucipir binding was slightly increased in the inferior frontal lobes in the ROI based analysis, but these results were not replicated in the voxel-based analysis. Autoradiography did not show specific binding in svPPA cases or in <jats:italic>C9orf72<\/jats:italic>-mutation carriers. In conclusion, temporal lobe <jats:sup>18<\/jats:sup>F-Flortaucipir retention was observed in some cases of svPPA, but the uptake was of a lower magnitude compared to AD dementia. <jats:italic>C9orf72<\/jats:italic>-mutation carriers exhibited none or limited <jats:sup>18<\/jats:sup>F-Flortaucipir retention, indicating that <jats:sup>18<\/jats:sup>F-Flortaucipir binding in TDP-43 proteinopathies is not a general TDP-43 related phenomenon.<\/jats:p>","DOI":"10.1038\/s41598-019-42625-9","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T10:02:52Z","timestamp":1555322572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["18F-Flortaucipir in TDP-43 associated frontotemporal dementia"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Santillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Landqvist","family":"Wald\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vestberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-9874","authenticated-orcid":false,"given":"D.","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"42625_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/jnnp-2013-306948","volume":"85","author":"L Chare","year":"2014","unstructured":"Chare, L. et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry 85, 865\u2013870, https:\/\/doi.org\/10.1136\/jnnp-2013-306948 (2014).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"42625_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014, https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6 (2011).","journal-title":"Neurology"},{"key":"42625_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/brain\/awp248","volume":"133","author":"JR Hodges","year":"2010","unstructured":"Hodges, J. R. et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 133, 300\u2013306, https:\/\/doi.org\/10.1093\/brain\/awp248 (2010).","journal-title":"Brain"},{"key":"42625_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bpa.12486","volume":"27","author":"DMA Mann","year":"2017","unstructured":"Mann, D. M. A. & Snowden, J. S. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol 27, 723\u2013736, https:\/\/doi.org\/10.1111\/bpa.12486 (2017).","journal-title":"Brain Pathol"},{"key":"42625_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IR Mackenzie","year":"2011","unstructured":"Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122, 111\u2013113, https:\/\/doi.org\/10.1007\/s00401-011-0845-8 (2011).","journal-title":"Acta Neuropathol"},{"key":"42625_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00259-015-3231-2","volume":"43","author":"M Dani","year":"2016","unstructured":"Dani, M., Brooks, D. J. & Edison, P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging 43, 1139\u20131150, https:\/\/doi.org\/10.1007\/s00259-015-3231-2 (2016).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"42625_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada, R. et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med 57, 208\u2013214, https:\/\/doi.org\/10.2967\/jnumed.115.164848 (2016).","journal-title":"J Nucl Med"},{"key":"42625_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2967\/jnumed.115.160127","volume":"56","author":"Y Kimura","year":"2015","unstructured":"Kimura, Y. et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. J Nucl Med 56, 1359\u20131365, https:\/\/doi.org\/10.2967\/jnumed.115.160127 (2015).","journal-title":"J Nucl Med"},{"key":"42625_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"CF Xia","year":"2013","unstructured":"Xia, C. F. et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement 9, 666\u2013676, https:\/\/doi.org\/10.1016\/j.jalz.2012.11.008 (2013).","journal-title":"Alzheimers Dement"},{"key":"42625_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87, 375\u2013383, https:\/\/doi.org\/10.1212\/WNL.0000000000002892 (2016).","journal-title":"Neurology"},{"key":"42625_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79, 110\u2013119, https:\/\/doi.org\/10.1002\/ana.24546 (2016).","journal-title":"Ann Neurol"},{"key":"42625_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe, V. J. et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4, 58, https:\/\/doi.org\/10.1186\/s40478-016-0315-6 (2016).","journal-title":"Acta Neuropathol Commun"},{"key":"42625_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marquie","year":"2015","unstructured":"Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78, 787\u2013800, https:\/\/doi.org\/10.1002\/ana.24517 (2015).","journal-title":"Ann Neurol"},{"key":"42625_CR14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567, https:\/\/doi.org\/10.1093\/brain\/aww027 (2016).","journal-title":"Brain"},{"key":"42625_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander, K. et al. Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimers Dement 12, 1116\u20131124, https:\/\/doi.org\/10.1016\/j.jalz.2016.01.003 (2016).","journal-title":"Alzheimers Dement"},{"key":"42625_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl, M. et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron 89, 971\u2013982, https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028 (2016).","journal-title":"Neuron"},{"key":"42625_CR17","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Scholl","year":"2017","unstructured":"Scholl, M. et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain 140, 2286\u20132294, https:\/\/doi.org\/10.1093\/brain\/awx171 (2017).","journal-title":"Brain"},{"key":"42625_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/JAD-151004","volume":"51","author":"R Smith","year":"2016","unstructured":"Smith, R. et al. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer\u2019s Disease Patient with Presenilin-1 Mutation. J Alzheimers Dis 51, 339\u2013343, https:\/\/doi.org\/10.3233\/JAD-151004 (2016).","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"42625_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/jnnp-2017-316402","volume":"89","author":"W R Bevan-Jones","year":"2017","unstructured":"Bevan-Jones, W. R. et al. [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry, https:\/\/doi.org\/10.1136\/jnnp-2017-316402 (2017).","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"10","key":"42625_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/jnnp-2017-316409","volume":"89","author":"Sara J Makaretz","year":"2017","unstructured":"Makaretz, S. J. et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry, https:\/\/doi.org\/10.1136\/jnnp-2017-316409 (2017).","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"42625_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/acn3.631","volume":"5","author":"RW Bevan-Jones","year":"2018","unstructured":"Bevan-Jones, R. W. et al. [(18)F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Ann Clin Transl Neurol 5, 1292\u20131296, https:\/\/doi.org\/10.1002\/acn3.631 (2018).","journal-title":"Ann Clin Transl Neurol"},{"key":"42625_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00008469-200112000-00003","volume":"10","author":"J Manjer","year":"2001","unstructured":"Manjer, J. et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10, 489\u2013499 (2001).","journal-title":"Eur J Cancer Prev"},{"key":"42625_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/brain\/awp037","volume":"132","author":"D Chan","year":"2009","unstructured":"Chan, D. et al. The clinical profile of right temporal lobe atrophy. Brain 132, 1287\u20131298, https:\/\/doi.org\/10.1093\/brain\/awp037 (2009).","journal-title":"Brain"},{"key":"42625_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.neuroimage.2007.03.024","volume":"36","author":"ML Schroeter","year":"2007","unstructured":"Schroeter, M. L., Raczka, K., Neumann, J. & Yves von Cramon, D. Towards a nosology for frontotemporal lobar degenerations-a meta-analysis involving 267 subjects. Neuroimage 36, 497\u2013510, https:\/\/doi.org\/10.1016\/j.neuroimage.2007.03.024 (2007).","journal-title":"Neuroimage"},{"key":"42625_CR25","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477, https:\/\/doi.org\/10.1093\/brain\/awr179 (2011).","journal-title":"Brain"},{"key":"42625_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall, S. et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol 69, 1445\u20131452, https:\/\/doi.org\/10.1001\/archneurol.2012.1654 (2012).","journal-title":"Arch Neurol"},{"key":"42625_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist, S. et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 8, 1214, https:\/\/doi.org\/10.1038\/s41467-017-01150-x (2017).","journal-title":"Nat Commun"},{"key":"42625_CR28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell, L. et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 55, 1623\u20131628, https:\/\/doi.org\/10.2967\/jnumed.114.142109 (2014).","journal-title":"J Nucl Med"},{"key":"42625_CR29","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze, S. et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol 74, 1492\u20131501, https:\/\/doi.org\/10.1001\/jamaneurol.2017.2814 (2017).","journal-title":"JAMA Neurol"},{"key":"42625_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7, 263\u2013269, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 (2011).","journal-title":"Alzheimers Dement"},{"key":"42625_CR31","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/brain\/aww163","volume":"139","author":"R Smith","year":"2016","unstructured":"Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372\u20132379, https:\/\/doi.org\/10.1093\/brain\/aww163 (2016).","journal-title":"Brain"},{"key":"42625_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.116.174508","volume":"58","author":"A Hahn","year":"2017","unstructured":"Hahn, A. et al. Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology. J Nucl Med 58, 623\u2013631, https:\/\/doi.org\/10.2967\/jnumed.116.174508 (2017).","journal-title":"J Nucl Med"},{"key":"42625_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker, S. L., Maass, A. & Jagust, W. J. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief 15, 648\u2013657, https:\/\/doi.org\/10.1016\/j.dib.2017.10.024 (2017).","journal-title":"Data Brief"},{"key":"42625_CR34","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset, O. G., Ma, Y. & Evans, A. C. Correction for partial volume effects in PET: principle and validation. J Nucl Med 39, 904\u2013911 (1998).","journal-title":"J Nucl Med"},{"key":"42625_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/2051-5960-2-70","volume":"2","author":"YS Davidson","year":"2014","unstructured":"Davidson, Y. S. et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2, 70, https:\/\/doi.org\/10.1186\/2051-5960-2-70 (2014).","journal-title":"Acta Neuropathol Commun"},{"key":"42625_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/brain\/awr361","volume":"135","author":"CJ Mahoney","year":"2012","unstructured":"Mahoney, C. J. et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135, 736\u2013750, https:\/\/doi.org\/10.1093\/brain\/awr361 (2012).","journal-title":"Brain"},{"key":"42625_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.24885","volume":"81","author":"EG Spinelli","year":"2017","unstructured":"Spinelli, E. G. et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 81, 430\u2013443, https:\/\/doi.org\/10.1002\/ana.24885 (2017).","journal-title":"Ann Neurol"},{"key":"42625_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00401-011-0907-y","volume":"122","author":"ME Murray","year":"2011","unstructured":"Murray, M. E. et al. Clinical and neuropathologic heterogeneity of c9FTD\/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122, 673\u2013690, https:\/\/doi.org\/10.1007\/s00401-011-0907-y (2011).","journal-title":"Acta Neuropathol"},{"key":"42625_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng, K. P. et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther 9, 25, https:\/\/doi.org\/10.1186\/s13195-017-0253-y (2017).","journal-title":"Alzheimers Res Ther"},{"key":"42625_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11307-017-1143-1","volume":"20","author":"AK Hansen","year":"2018","unstructured":"Hansen, A. K., Brooks, D. J. & Borghammer, P. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([F-18]-AV-1451) Binding. Mol Imaging Biol 20, 356\u2013360, https:\/\/doi.org\/10.1007\/s11307-017-1143-1 (2018).","journal-title":"Mol Imaging Biol"},{"key":"42625_CR41","doi-asserted-by":"publisher","unstructured":"Smith, R., Scholl, M., Londos, E., Ohlsson, T. & Hansson, O. F-18-AV-1451 in Parkinson\u2019s Disease with and without dementia and in Dementia with Lewy Bodies. Sci Rep-Uk 8, https:\/\/doi.org\/10.1038\/s41598-018-23041-x (2018).","DOI":"10.1038\/s41598-018-23041-x"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42625-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:41:10Z","timestamp":1671266470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42625"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42625-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"3 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.F.S., M.L.W., O.S., D.B., S.V., D.v.W. and J.v.S. declare no competing interests. R.S. has served as a consultant for Roche. M.H. is a full-time employee of Roche Diagnostics. O.H. has acquired research support (for the institution) from Roche, G.E. Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy\/speaker fees (paid to the institution) from Biogen, Roche, and Fujirebio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6082"}}